Overview

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I trial of LDE225 for the treatment of steroid-refractory chronic Graft Versus Host Disease (GVHD).
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Novartis